Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tempus AI — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B), while Tempus AI trades at $61.16 (market cap $11.67B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.4× Tempus AI's market cap, and Marsh & McLennan Companies, Inc. pays a 2.19% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MRSH | TEM | |
|---|---|---|
Market Cap | $86.15B | $11.67B |
Sector | Financials | Broad Market / Factor |
52-Week High | $207.02 | $103.25 |
52-Week Low | $157.32 | $41.55 |
Enterprise Value | $106.83B | $12.30B |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals, including consistent earnings beats, a 14.24% net income margin, and robust cash flow. Recent news highlights growth in healthcare consulting and cyber risk services, supporting revenue expansion.
Outlook remains positive with a consensus price target of $208.63, offering 15% upside. Risks include economic sensitivity and debt levels, but analyst sentiment leans bullish with 30% buy ratings. The stock presents a growth opportunity in professional services, backed by solid financials and strategic initiatives.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
